Literature DB >> 17434047

The expanding spectrum of Galli-Galli disease.

Laila El Shabrawi-Caelen1, Arno Rütten, Helmut Kerl.   

Abstract

Galli-Galli disease (GGD), a rare genodermatosis in the spectrum of reticulate hyperpigmentation, is regarded as an acantholytic variant of Dowling-Degos disease. We herein report two patients with GGD exhibiting erythematous scaly plaques and lentigo-like macules on the trunk and lower extremities, rather than the characteristic reticulate hyperpigmented macules of large body folds. Digitate elongations of rete ridges coupled with foci of acantholysis were the clues to the diagnosis. A high index of suspicion is needed to diagnose GGD that lacks the characteristic reticulate hyperpigmentation of large body folds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434047     DOI: 10.1016/j.jaad.2006.10.987

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  [Galli-Galli disease. Clinical and histopathological investigation using a case series of 18 patients].

Authors:  S Hanneken; A Rütten; S Eigelshoven; M Braun-Falco; S M Pasternack; T Ruzicka; M M Nöthen; R C Betz; R Kruse
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

2.  Galli-galli disease: a rare acantholytic variant of dowling-degos disease.

Authors:  J Gomes; J Labareda; I Viana
Journal:  Case Rep Med       Date:  2011-05-05

3.  Acitretin therapy for Galli-Galli disease.

Authors:  Chandler W Rundle; Solveig Ophaug; Eric L Simpson
Journal:  JAAD Case Rep       Date:  2020-04-30

4.  Exacerbation of Galli-Galli Disease Following Dialysis Treatment: A Case Report and Review of Aggravating Factors.

Authors:  Tejas P Joshi; Sally Shaver; Jaime Tschen
Journal:  Cureus       Date:  2021-06-02

5.  The First Report of KRT5 Mutation Underlying Acantholytic Dowling-Degos Disease with Mottled Hypopigmentation in an Indian Family.

Authors:  Shyam Verma; Sandra M Pasternack; Arno Rütten; Thomas Ruzicka; Regina C Betz; Sandra Hanneken
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.